Hi-Clearance Inc. AI Stock Analysis
Hi-Clearance Inc. (1788) AI Stock Analysis
Hi-Clearance Inc.
(TPEx:1788)
Hi-Clearance scores moderately. Its financial foundation is sound, led by a conservative balance sheet (60% equity funded, debt-to-equity of 0.35, ~12% ROE) and consistent profitability, though modest operating margin compression and a 21% drop in operating cash flow temper the picture. Valuation is the key support: a 14.2x P/E and a 5.6% dividend yield provide value and income appeal in a low-volatility stock. The main drag is technical weakness, with the price below all major moving averages and a negative MACD, although deeply oversold RSI and Stochastic readings suggest downside momentum may be nearing exhaustion. Overall, a defensive, income-oriented holding with limited near-term growth acceleration.
Hi-Clearance Inc. (1788) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 5.61B
- Dividend Yield
- 5.60%
- Average Volume (3M)
- 20.31K
- Price to Earnings (P/E)
- 14.2
- Beta (1Y)
- 0.02
- Revenue Growth
- 7.58%
- EPS Growth
- 13.04%
- Country
- TW
- Employees
- 150
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Hi-Clearance Inc. Business Overview & Revenue Model
Company Description
Established in 1989 and headquartered in New Taipei City, Taiwan, Hi-Clearance Inc. is a prominent supplier of medical devices and associated services throughout Taiwan. The company's comprehensive product range addresses various healthcare sectors,...
Hi-Clearance Inc. Financial Statement Overview
Summary
Solid but unspectacular fundamentals. The balance sheet is the standout (score 73): equity funds roughly 60% of assets, debt-to-equity is a comfortable 0.35, and ROE is a dependable ~12%, though borrowings have crept up from NT$645M to NT$1.06B. The income statement (66) shows revenue recovering ~5% to NT$4.28B with a stable ~26.7% gross margin, but operating margin slipped to 9.9% from 11.2%, signalling no operating leverage. Cash flow (61) is the weakest link: operating cash flow fell ~21% to NT$400.7M and the improvement in free cash flow to NT$295.4M came from lower capex rather than stronger operations, with a history of volatile FCF.
Income Statement
66PositiveBalance Sheet
73PositiveCash Flow
61Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.28B | 4.07B | 3.90B | 4.69B | 3.68B |
| Gross Profit | 1.22B | 1.14B | 1.07B | 1.02B | 1.05B | 968.97M |
| EBITDA | 631.99M | 620.80M | 636.07M | 580.00M | 625.93M | 595.93M |
| Net Income | 391.96M | 368.51M | 359.69M | 347.98M | 366.43M | 348.59M |
Balance Sheet | ||||||
| Total Assets | 5.29B | 5.08B | 4.96B | 4.62B | 4.51B | 4.44B |
| Cash, Cash Equivalents and Short-Term Investments | 564.80M | 599.45M | 545.53M | 453.10M | 417.23M | 404.56M |
| Total Debt | 1.16B | 1.06B | 971.65M | 644.74M | 1.03B | 1.14B |
| Total Liabilities | 2.34B | 2.03B | 1.96B | 1.63B | 2.07B | 2.13B |
| Stockholders Equity | 2.95B | 3.05B | 3.00B | 2.98B | 2.44B | 2.30B |
Cash Flow | ||||||
| Free Cash Flow | 263.60M | 295.39M | 225.55M | 371.54M | 300.49M | 137.28M |
| Operating Cash Flow | 354.70M | 400.70M | 510.12M | 433.49M | 403.16M | 287.79M |
| Investing Cash Flow | -119.56M | -98.43M | -377.19M | -66.45M | -82.61M | -158.04M |
| Financing Cash Flow | -279.22M | -241.32M | -122.33M | -288.44M | -342.13M | -196.90M |
Hi-Clearance Inc. Peers Comparison
Overall Rating
TW:416670Outperform
TW:412668Neutral
TW:173464Neutral- TW:178863Neutral
TW:416359Neutral
TW:179945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.88 | ― | ― | ― | ― |
| TW:4126 | 68Neutral | TWD 5.39B | 12.59 | ― | 6.06% | 1.32% | 7.25% |
| TW:1734 | 64Neutral | TWD 6.07B | 16.18 | ― | 3.13% | 2.44% | -3.96% |
| TW:1788 | 63Neutral | TWD 5.57B | 14.20 | ― | 5.60% | 7.58% | 13.04% |
| TW:4163 | 59Neutral | TWD 6.41B | 20.82 | ― | 2.77% | 4.16% | 40.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1799 | 45Neutral | TWD 6.24B | -192.69 | ― | ― | 59.53% | 83.16% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1788 | Hi-Clearance Inc. | 125.00 | -5.42 | -4.16% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.10 | 1.71 | 6.02% | |
| TW:1799 | Easywell Biomedicals, Inc. | 25.10 | -8.55 | -25.41% | |
| TW:4126 | Pacific Hospital Supply Co., Ltd. | 74.30 | -9.30 | -11.13% | |
| TW:4163 | Intai Technology Corp. | 126.50 | 29.94 | 31.00% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.50 | -2.10 | -8.54% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026